

balance:

(noun)

PUT IN A STEADY
POSITION

Running a company
requires balance.



FINANCIAL SUMMARY

10 Years' Performance

₹ In lakhs

CAPITAL ACCOUNT

	2009-10	2010-11	2011-12	2012-13	2013-14	2014-15	2015-16	2016-17	2017-18	2018-19
Share Capital	139	418	418	418	418	418	1,253	1,253	1,253	1,253
Reserves	5,241	5,716	6,503	7,145	8,171	9,672	10,958	12,802	13,709	15,207
Borrowings	301	696	702	52	-	-	211	-	244	439
Gross Block	1,559	1,786	1,936	2,294	2,387	2,295	3,361	3,364	2,640	6,036
Net Block	902	1,028	1,095	1,308	1,233	982	1,850	1,759	2,262	5,502

REVENUE ACCOUNT

	2009-10	2010-11	2011-12	2012-13	2013-14	2014-15	2015-16	2016-17	2017-18	2018-19
Total Revenue	17,323	17,903	22,908	24,490	27,055	28,874	32,973	22,454	24,863	32,537
Profit before Depreciation & Tax	1,870	1,861	1,937	1,935	2,722	3,513	4,020	2,955	2,525	3,406
Profit before Tax	1,754	1,751	1,805	1,768	2,548	3,186	3,794	2,759	2,342	3,240
Profit After Tax	1,255	1,229	1,285	1,253	1,759	2,199	2,580	2,005	1,651	2,337
Earnings Per Share (₹)	45.07	14.71	15.38	15.01	21.06	26.00	10.30	8.00	6.59	9.00
Dividend Per Share (₹)	10.00	5.00	5.50	6.00	7.75	7.00	2.50	2.50	2.75	2.75

Notes :

- 1) EPS & DPS reported w.e.f. FY 2015-16 is after giving effect to Bonus Issue of Shares in the ratio of 2:1 i.e. 2 Bonus Shares for each Equity Share held.
- 2) Figures for the FY 2016-17 and onwards are reported as per Ind AS requirements.
- 3) Gross Block reported above for the FY 2017-18 is as per Ind AS transition provision, however comparable value of gross block as per old IGAAP is Rs. 4,050/- Lakhs.

CONTENTS

Particulars	Page Nos.
Corporate Information	2
MD's Message to the Shareholders	3
List of Board of Directors	4
List of Senior Management and Key Managerial Personnel	6
A tribute to Dilip G. Shah	7
Notice	8
Directors' Report	17
Management Discussion and Analysis	44
Corporate Governance Report	47
Certificate on Corporate Governance	63
Independent Auditor's Report	64
Balance Sheet as on March 31, 2019	72
Statement of Profit and Loss for the year ended on March 31, 2019	73
Cash Flow Statement	74
Notes to Financial Statements	77
Attendance Slip and Proxy Form	-

ANUH PHARMA LTD.

CIN: L24230MH1960PLC011586

Fifty-Ninth Annual Report of the Board of Directors with the Audited Statement of Accounts for the year ended March 31, 2019

Board of Directors	: Mr. Jasvantlal Shah Mr. Bipin Shah Mr. Lalitkumar Shah Mr. Bharat Shah Mr. Dilip Shah <i>(Passed away on 22/02/2019)</i> Mr. Arun Todarwal Mr. Sandeep Joshi <i>(Resigned w.e.f. 31/03/2019)</i> Ms. Rajeshree Gor <i>(Resigned w.e.f. 30/07/2018)</i> Mr. Samir Shah Mr. Ketan Shah Mr. Ritesh Shah Mr. Vivek Shah Dr. (Ms.) Mita Dixit <i>(Appointed w.e.f. 08/02/2019)</i> Mr. Harmanbhai Patel <i>(Appointed w.e.f. 22/05/2019)</i>	Chairman - Independent Director Managing Director Director Director Independent Director Independent Director Independent Director Director Director Director Whole Time Director & CEO Whole Time Director & CEO (R&D) Independent Director Additional Director	(DIN: 00372600) (DIN: 00083244) (DIN: 00396345) (DIN: 00083354) (DIN: 01989812) (DIN: 00020916) (DIN: 00516409) (DIN: 06873519) (DIN: 00157396) (DIN: 00083326) (DIN: 02496729) (DIN: 02878724) (DIN: 08198165) (DIN: 07342390)
Chief Financial Officer	: Mr. Darshan Rampariya		
Company Secretary & Compliance Officer	: Ms. Ashwini Ambrale		
Auditors	: M/s. Jayantilal Thakkar & Co. Chartered Accountants, (Firm Registration No. 104133W)		
Bankers	: HDFC Bank Ltd.		
Registrar and Share Transfer Agent	: Bigshare Services Private Limited 1 st Floor, Bharat Tin Works Building, Opp. Vasant Oasis Makwana Road, Marol, Andheri East, Mumbai 400059 Tel: +91-22-6263 8200 Fax: +91-22-6263 8299 Email: investor@bigshareonline.com Web: www.bigshareonline.com		
Registered Office	: 3-A, Shivsagar Estate, North Wing, Dr. Annie Besant Road, Worli, Mumbai - 400018 Tel : +91-22-6622 7575 Fax: +91-22-6622 7600 Email: anuh@sk1932.com Web: www.anuhpharma.com		
Factory	: E-17/3, E-17/4 & E-18, MIDC, Tarapur, Boisar, Dist. Palghar - 401506 Tel : +91-7410055574/75		
R & D Division	: A-514, TTC Industrial Area, MIDC, Mahape, Navi Mumbai - 400701 Tel : +91-22-4119 3333 Fax: +91-22-4119 3300 Email: research@anuhpharma.com Web: www.aplrnd.com		

Managing Director's Message to the Shareholders



Mr. Bipin N. Shah

Managing Director

Dear Shareholders,

It gives me great pleasure to present our Company's 59th Annual Report. In a nutshell.

Our Operational Revenue for the financial year 2018-19 amounted to ₹ 32,066 lakhs as against ₹ 24,125 lakhs for the previous year, "an increase of 32.92 %".

Our PBT has gone from ₹ 2,342 lakhs to ₹ 3,240 lakhs, "increase of 38.34 %" on year on year basis.

One of the great privileges of working in pharmaceutical industry is the opportunity to directly contribute towards the advancement of human quality of life.

This has always been our greatest source of purpose in propelling Anuh Pharma forward.

ENHANCING PRESENCE IN BULK DRUG SEGMENT:

We continue to allocate total resources towards building the API & Bulk Drug Segment. We have a state of the art R & D facility in Navi Mumbai which works day & night on the development of newer & better pharmaceutical raw material.

An advance stage works is going on for the following products:

- 1) Aripiprazole
- 2) Olanzapine
- 3) Fexofenadine
- 4) Sitagliptin
- 5) Gliclazide
- 6) Celecoxib

GLOBAL cGMP COMPLIANCE:

Adherence to the stringent cGMP requirements of global regulators is a non-compromising objective for us. Compliance to this standards has become a key determinantal of future success for the API industry. We continue to invest significant time & resource in ensuring that we remain committed to 24/7 cGMP compliance over the past years our cGMP capabilities have been increased significantly. Talent with long standing global exercise has enhanced one abilities in this pertinent area. There are also targeting appropriate technology based solutions to facilitate cGMP compliance with an increased focus on requisite manpower training.

TRANSFORMATION:

It is obvious to generate long term sustainable value for Shareholders, business need to continuously involve & transform themselves to build a strong foundation for future growth.

At Anuh Pharma we have decided on a transformational journey to make Anuh Pharma a Company that is in tune with the times.

EXPANSION PROJECT:

Our futuristic & world class expansion project is nearing its completion, we propose to commission the plant by September 2019.

We will be increasing on installed capacity from 900 metric from to 1500 metric tons in the first phase & we will be adding 4 products in the current financial year.

With Warm Regards,

Mr. Bipin N. Shah
Managing Director
Anuh Pharma Ltd.

Board of Directors



Mr. Jasvantlal G. Shah
Chairman



Mr. Bipin N. Shah
Managing Director



Mr. Lalitkumar P. Shah
Director



Mr. Bharat N. Shah
Director



Mr. Arun L. Todarwal
Director



Dr. (Ms.) Mita C. Dixit
Director

Board of Directors



Mr. Samir J. Shah
Director



Mr. Ketan L. Shah
Director



Mr. Ritesh B. Shah
Whole Time Director & CEO



Mr. Vivek B. Shah
Whole Time Director & CEO (R&D)



Mr. Harmanbhai T. Patel
Additional Director

Senior Management & Key Managerial Personnel



Mr. Rajendrakumar C. Kotadia
Vice President - Marketing



Dr. Rajendra M. Agrawal
Vice President - Technical



Mr. Bhushan S. Rajput
Vice President - QA



Mr. Darshan D. Rampariya
Chief Financial Officer



Dr. Uday V. Korgaonkar
Head of the Department - R & D



Dr. Sushil J. Dheer
General Manager - R & D



Mr. Girish P. Mandlekar
General Manager - Works



Mr. Tejas S. Patel
General Manager - QA



Mr. Surendra U. Rai
QC Assistant General Manager



Mr. Ketan N. Shah
Senior Marketing Executive



Mr. Gaurav S. Shah
Head Anti Malarials



Mr. Kaushal H. Shroff
Senior Marketing Executive



Mr. Nilesh S. Mohare
QA Assistant General Manager



Ms. Ashwini S. Ambrale
Company Secretary &
Compliance Officer



Mr. Monil R. Shah
Marketing & Business
Development Executive



DILIP GIRDHARLAL SHAH (1941 - 2019)

Anuh Pharma has been fortunate to have the blessings and guidance of several proficient people. Amongst them, we wish to remember **Shri. Dilip G. Shah** who passed away on 22nd February, 2019. This unfortunate event came as a shock to everyone. He had been a long-standing Member of Anuh Pharma Ltd.'s Board and steered the Company through great transitions.

Shri. Dilip G. Shah had 52 years of varied experience in the pharmaceutical industry. He was the Secretary-General of the Indian Pharmaceutical Alliance, Member of the Expert Review Committee of Access to Medicine (ATM) Index; Member of the CPHI International Advisory Board; and Member of the Board of Advisors of Pharmabiz.com. He was on the board of prestigious companies, and also the CEO of Vision Consulting Group, a firm specialized in strategic planning.

While this is indeed a personal loss to the Company, it would be very apt to say that we lost a legend of the Indian pharmaceutical industry.

On behalf of all the Employees, Management, Board Members and Shareholders, we pray that his soul rests in peace.

NOTICE

FIFTY NINTH ANNUAL GENERAL MEETING of the Members of ANUH PHARMA LIMITED will be held on Thursday, August 22, 2019 at 03.00 PM at Hall of Harmony, Nehru Centre, Dr. Annie Besant Road, Worli, Mumbai - 400018 to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and adopt the Audited Financial Statements of the Company for the financial year ended March 31, 2019, including Audited Balance Sheet as at March 31, 2019 and the Statement of Profit & Loss for the year ended on that date together with the Reports of the Board of Directors and Auditors thereon for the said year.
2. To declare a final Dividend of ₹ 2.75/- per Equity Share of the Company for the financial year 2018-19.
3. To appoint a Director in place of Mr. Ritesh B. Shah (DIN: 02496729) who retires by rotation and, being eligible offers himself for re-appointment.
4. To appoint a Director in place of Mr. Vivek B. Shah (DIN: 02878724) who retires by rotation and, being eligible offers himself for re-appointment.

SPECIAL BUSINESS :

5. To consider and, if thought fit, to pass, with or without modification(s), the following resolution as an **Ordinary Resolution**:

“RESOLVED THAT pursuant to the provisions of Section 148 and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), the remuneration of ₹ 1,10,000/- plus applicable tax and reimbursement of the out of pocket expenses, if any, payable to Mr. Ankit Kishor Chande, Cost Accountant, (Certificate of Practice No. 34051) being a Cost Auditor, to conduct the audit of the Cost Accounting records related to Bulk Drugs of the Company for the financial year 2019-20, be and is hereby ratified.

RESOLVED FURTHER THAT Mr. Bipin N. Shah, Managing Director (DIN: 00083244), Mr. Bharat N. Shah (DIN: 00083354), Mr. Lalitkumar P. Shah, (DIN: 00396345) Directors or the Company Secretary of the Company be and is hereby severally authorized to take all such necessary steps and actions and authorized to do all the necessary formalities and to sign and submit the necessary papers and forms with required authorities including E-Form with Registrar of Companies to give effect to this resolution.”

6. To consider and, if thought fit, to pass, with or without modification(s), the following resolution as a **Special Resolution**:

“RESOLVED THAT pursuant to provisions of Sections 149, 152, read with Schedule IV and other applicable provisions, if any, of the Companies Act, 2013 (‘Act’) and the Rules framed thereunder (including any statutory modification(s) or re-enactment thereof, for the time being in force) Mr. Harmanbhai Tulsibhai Patel (DIN: 07342390), who was appointed as an Additional Director of the Company by the Board of Directors pursuant to the provisions of Section 161 of the Companies Act, 2013 and in respect of whom the Company has received a notice, in writing, from a member under Section 160 of the Act, proposing his candidature for the office of Independent Director, be and is hereby appointed as an Independent Director of the Company for 5 (Five) consecutive years to hold office w.e.f. August 22, 2019 upto August 21, 2024 subject to the requisite approval of the Shareholders and not liable to retire by rotation.

RESOLVED FURTHER THAT Mr. Bipin N. Shah, Managing Director, (DIN: 00083244), Mr. Bharat N. Shah (DIN: 00083354), Mr. Lalitkumar P. Shah, (DIN: 00396345) Directors or the Company Secretary of the Company be and is hereby severally authorized to take all such necessary steps and actions and authorized to do all the necessary formalities and to sign and submit the necessary papers and forms with required authorities including E-Form with Registrar of Companies to give effect to this resolution.

7. To consider and, if thought fit, to pass, with or without modification(s), the following resolution as a **Special Resolution**:

“RESOLVED THAT pursuant to the provisions of Section 197 read with Part I and Section I of Part II of Schedule V and other applicable provisions, if any, of the Companies Act, 2013 (including any statutory modification or re-enactment thereof